Cargando…

Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study

Hepatitis C virus and alcoholic liver disease are major causes of chronic liver diseases worldwide. Little is known about differences between chronic hepatitis C and alcoholic liver disease in terms of lymphocytes’ sub-population. Aim of the present study was to compare the sub-populations of lympho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romanelli, Roberto Giulio, Vitiello, Gianfranco, Gitto, Stefano, Giudizi, Maria Grazia, Biagiotti, Roberta, Carraresi, Alessia, Vizzutti, Francesco, Laffi, Giacomo, Almerigogna, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290250/ https://www.ncbi.nlm.nih.gov/pubmed/32524881 http://dx.doi.org/10.1177/2058738420929587

Ejemplares similares

Bench to bedside review of myositis autoantibodies
por: Palterer, Boaz, et al.
Publicado: (2018)

Spontaneous in vitro differentiation of a myoepithelial cell line (PA 16/23) from a pleomorphic adenoma of the parotid gland is associated with reduced production of the autocrine growth factor interleukin 6.
por: Gallo, O., et al.
Publicado: (1994)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications
por: Becatti, Matteo, et al.
Publicado: (2020)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

Aggressive Gastric Carcinoma Producing Alpha-Fetoprotein: A Case Report and Review of the Literature
por: Lunghi, A., et al.
Publicado: (2014)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

High mortality of pneumonia in cirrhotic patients with ascites
por: Hung, Tsung-Hsing, et al.
Publicado: (2013)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

Current approaches to the management of patients with cirrhotic ascites
por: Garbuzenko, Dmitry Victorovich, et al.
Publicado: (2019)

Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
por: Balcar, Lorenz, et al.
Publicado: (2022)

The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive changes in Cirrhotic Patients with Ascites
por: Shahed, Forhad Hossain Md, et al.
Publicado: (2016)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Bacteriologic study of cirrhotic patients with non-neutrocytic ascites
por: Dabiri, Hossein, et al.
Publicado: (2014)

Alteration of the serum microbiome composition in cirrhotic patients with ascites
por: Santiago, Alba, et al.
Publicado: (2016)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Predictors of Spontaneous Bacterial Peritonitis in Patients with Cirrhotic Ascites
por: Metwally, Khaled, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Undifferentiated shock in a cirrhotic patient: Ascites matters
por: Xenou, Antigoni, et al.
Publicado: (2021)

Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients
por: Traykova, Daniela, et al.
Publicado: (2017)

Nutritional Deficiencies and Clinical Practices in Decompensated Cirrhotics With Hepatic Encephalopathy
por: Panchani, Nishah N, et al.
Publicado: (2022)

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
por: Tarao, Kazuo, et al.
Publicado: (2021)

The Role of Serum Procalcitonin Levels in Predicting Ascitic Fluid Infection in Hospitalized Cirrhotic and Non-cirrhotic Patients
por: Cekin, Yesim, et al.
Publicado: (2013)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving
por: Bloom, Patricia P., et al.
Publicado: (2021)

Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
por: Zhang, Zhi-Hao, et al.
Publicado: (2017)

Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview
por: Tampaki, Maria, et al.
Publicado: (2023)

Ascitic Bacterial Composition Is Associated With Clinical Outcomes in Cirrhotic Patients With Culture-Negative and Non-neutrocytic Ascites
por: Chen, Yanfei, et al.
Publicado: (2018)

Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites
por: Kalambokis, Georgios N., et al.
Publicado: (2011)

The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX(©) Catheter
por: Reinglas, Jason, et al.
Publicado: (2016)

Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians
por: Gallo, Andrea, et al.
Publicado: (2020)

Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
por: Aagaard, Niels Kristian, et al.
Publicado: (2022)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Serum and ascitic D-dimer in cirrhotic patients with spontaneous bacterial peritonitis
por: El Gohary, Ahmed M., et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b35q29bbdc39euviu7ljfs26b9